Inhibikase Therapeutics, Inc. (IKT) Total liabilities 2020–2024
Inhibikase Therapeutics, Inc. (IKT) total liabilities at each fiscal year-end, per SEC filings.
$3.7MFY2024 · since FY2020: $5.0M → $3.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $3.7M | +5.8% |
| FY2023 | $3.5M | -9.5% |
| FY2022 | $3.9M | -3.8% |
| FY2021 | $4.1M | -18.9% |
| FY2020 | $5.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice